A 59-year-old with HFrEF (LVEF 28%) on ACE inhibitor and beta-blocker remains symptomatic. Per 2022 HF guideline, which agent improves survival and sh...

Question

A 59-year-old with HFrEF (LVEF 28%) on ACE inhibitor and beta-blocker remains symptomatic. Per 2022 HF guideline, which agent improves survival and should be added (if K+ ≤5.0 and eGFR ≥30)?

Accepted Answer

Mineralocorticoid receptor antagonist

Answer

Hydrochlorothiazide

Answer

Diltiazem

Answer

Nifedipine

Answer

Ivabradine

"moderate" MCQ (SBA): Heart Failure with Reduced Ejection Fraction

A 59-year-old with HFrEF (LVEF 28%) on ACE inhibitor and beta-blocker remains symptomatic. Per 2022 HF guideline, which agent improves survival and should be added (if K+ ≤5.0 and eGFR ≥30)?